STOCK TITAN

Allarity Therapeutics (ALLR) Financials

ALLR NASDAQ
FY2025 annual
Revenue $320K n/m YoY
Net Income -$11.2M n/m YoY
Free Cash Flow -$14.8M n/m YoY
Operating Cash Flow -$14.8M n/m YoY
Market Cap $13.8M as of Nov 19, 2026
Price / Sales 39.5x on $350K revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALLR SEC filings page.

Allarity Therapeutics, Inc. (ALLR) reported $320K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ALLR FY2025

Allarity remains a development-stage business, with minimal reported revenue, multi-million-dollar operating costs, and recurring reliance on outside financing.

FY2025’s cash economics are driven by spending rather than sales: research and development was $6.6M against revenue of just $320K. That mismatch sits behind operating cash flow of -$14.8M versus a net loss of $11.2M, meaning accounting losses understated the cash absorbed by operations.

The company’s cash conversion is weak because the outflow is operational: operating cash flow was -$14.8M, while capital expenditures were only $8K. Free cash flow was -$14.8M, nearly matching operating cash flow, so physical-asset reinvestment is not the main use of cash.

Liquidity looks more orderly than profitability: the current ratio was 2.1x and liabilities were 46.2% of assets. Liabilities fell 22.2% from FY2024, while positive financing cash flow of $10.6M shows external funding still supplemented operations.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Allarity Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
-10.63

Allarity Therapeutics, Inc. scores -10.63, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $130.2M against total assets of $18.3M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/7

Allarity Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Allarity Therapeutics, Inc. reported a net loss of $11.2M while operations used $14.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Allarity Therapeutics, Inc. reported an operating loss of $12.6M against $185K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$5K
YoYn/m
QoQn/m

Allarity Therapeutics, Inc. generated $5K in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$6.2M
YoYn/m
QoQn/m
5Y CAGRn/m

Allarity Therapeutics, Inc. reported a net loss of $6.2M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EBITDA

Not reported for Q3 2026.

EPS (Diluted)

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$2.9M
YoYn/m
QoQn/m

Allarity Therapeutics, Inc. recorded an outflow of $2.9M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$14.1M
YoY-16.6%
QoQ-17.0%
5Y CAGR+20.3%

Allarity Therapeutics, Inc. held $14.1M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
16M
YoY+1.2%
QoQ+0.5%

Allarity Therapeutics, Inc. had 16M shares outstanding in Q3 2026. This represents an increase of 1.2% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$4.2M
YoY+250.7%
QoQ+213.7%

Allarity Therapeutics, Inc. invested $4.2M in research and development in Q3 2026. This represents an increase of 250.7% from the same quarter a year earlier. Against the prior quarter it is up 213.7%.

Share Buybacks
$0
YoY-100.0%
QoQn/m

Allarity Therapeutics, Inc. repurchased no shares in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Capital Expenditures
$0
YoYn/m
QoQn/m

Allarity Therapeutics, Inc. reported no capital expenditure in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

ALLR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ALLR quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$5Kn/m$0n/m$25Kn/m$320K$0$0$0N/A
R&D Expenses$4.2M+250.7%$1.3M-42.1%$1.3M-7.6%$1.7M-9.4%$1.2M+17.8%$2.3M+119.4%$1.4M-35.3%$1.8M-29.6%
SG&A Expenses$1.3M-1.7%$1.3M-26.8%$1.4M-13.3%$1.6M-71.4%$1.3M-17.2%$1.8M-21.7%$1.6M-21.1%$5.5M+142.5%
Operating Income-$5.5Mn/m-$2.7Mn/m-$2.7Mn/m-$2.9Mn/m-$2.5Mn/m-$4.1Mn/m-$3.0Mn/m-$7.3Mn/m
EBITDAN/AN/AN/AN/AN/A-$4.1Mn/m-$3.0Mn/mN/A
Interest Expense$1.0M+1675.4%$719K+5891.7%$229K+301.8%N/A$57K+14.0%$12K-97.2%$57K-44.1%N/A
Income TaxN/AN/AN/A$0n/m$0n/m$0n/m$0n/m$0
Net Income-$6.2Mn/m-$3.4Mn/m-$2.8Mn/m-$3.4Mn/m-$2.8Mn/m-$2.3Mn/m-$2.7Mn/m-$7.5Mn/m
EPS (Basic)-$0.39n/m-$0.21n/m-$0.17n/m-$0.21-$0.19-$0.15-$0.25N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted), Diluted Shares (Avg).

ALLR Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ALLR quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$27.2M+30.9%$32.1M+51.5%$34.9M+17.5%$18.3M-19.4%$20.8M+2.1%$21.2M-31.3%$29.7M+148.4%$22.6M+90.9%
Current Assets$26.9M+31.3%$31.7M+51.9%$34.5M+17.3%$17.9M-19.8%$20.5M+0.5%$20.9M-2.0%$29.4M+1182.0%$22.3M+1033.5%
Cash & Equivalents$14.1M-16.6%$17.0M-4.6%$19.8M-21.4%$14.7M-24.8%$16.9M-8.7%$17.8M-7.4%$25.2M+7977.2%$19.5M+11666.9%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$29.5M+235.6%$28.6M+216.2%$28.0M+153.2%$8.4M-22.2%$8.8M+18.5%$9.0M-18.2%$11.1M-40.0%$10.8M-25.8%
Current Liabilities$29.5M+235.6%$28.6M+216.2%$28.0M+153.2%$8.4M-22.2%$8.8M+18.5%$9.0M-14.9%$11.1M-38.6%$10.8M-23.5%
Non-Current Liabilities$0n/m$0n/m$0n/m$0n/m$0n/m$0-100.0%$0-100.0%$0-100.0%
Total Equity-$2.3M-118.8%$3.5M-70.9%$6.9M-62.9%$9.8M-16.8%$12.0M-7.4%$12.2M-38.7%$18.7Mn/m$11.8Mn/m
Retained Earnings-$142.6Mn/m-$136.4Mn/m-$132.9Mn/m-$130.2Mn/m-$126.8Mn/m-$124.0Mn/m-$121.7Mn/m-$119.0Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ALLR Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ALLR quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$2.9Mn/m-$2.6Mn/m-$4.5Mn/m-$3.2Mn/m-$3.4Mn/m-$5.5Mn/m-$2.7Mn/m-$3.2Mn/m
Depreciation & AmortizationN/AN/AN/AN/AN/A$12K+1100.0%$11K+450.0%N/A
Stock-Based Compensation$191K+44.7%$188K+14.6%$160K+15.1%N/A$132K+676.5%$164K+645.5%$139Kn/mN/A
Capital Expenditures$0n/m$0n/m$64Kn/m$8K$0$0$0N/A
Free Cash Flow-$2.9Mn/m-$2.6Mn/m-$4.6Mn/mN/A-$3.4M-$5.5M-$2.7MN/A
Investing Cash Flow$0n/m$0n/m-$64Kn/m-$8K$0$0$0N/A
Financing Cash Flow$0-100.0%$0n/m$19.7M+77.2%-$240K-105.7%$2.3M-52.5%-$2.6M-109.7%$11.1M+707.5%$4.2M+711.3%
Share Buybacks$0-100.0%$0-100.0%$262Kn/m$484Kn/m$141Kn/m$2.6M$0$0

Not reported in any period shown, so not listed: Dividends Paid.

ALLR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ALLR quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-110140.0%N/A-10752.0%-911.9%N/AN/AN/AN/A
Net Margin-124000.0%N/A-11000.0%-1054.1%N/AN/AN/AN/A
Return on EquityN/A-96.3%-77.2pp-39.7%-25.1pp-34.3%+28.8pp-23.4%+66.0pp-19.1%-10.9pp-14.6%-63.1%
Return on Assets-22.8%-9.3pp-10.6%+0.3pp-7.9%+1.3pp-18.5%+14.4pp-13.5%+43.4pp-10.9%-5.7pp-9.2%+22.9pp-32.9%-18.4pp
Current Ratio0.91-1.4x1.11-1.2x1.23-1.4x2.13+0.1x2.33-0.4x2.31+0.3x2.66+2.5x2.06+1.9x
Liabilities-to-EquityN/A8.08+7.3x4.05+3.5x0.86-0.1x0.73+0.2x0.74+0.2x0.590.92
Asset Turnover0.000.0x0.000.0x0.000.0x0.020.000.000.00N/A
FCF Margin-57540.0%N/A-18228.0%N/AN/AN/AN/AN/A

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Allarity Therapeutics, Inc. ALLR FY2025 $320K -$11.2M N/A $13.8M —
Actuate Therapeutics, Inc. ACTU FY2025 N/A -$22.2M N/A $12.9M —
Akari Therapeutics plc AKTX FY2025 N/A -$17.3M N/A $15.6M —
Acumen Pharmaceuticals, Inc. ABOS FY2025 N/A -$121.3M N/A $14.0M —
NewcelX Ltd. NCEL FY2025 N/A -$8.3M N/A $15.5M —
Citius Pharmaceuticals Inc. CTXR FY2025 N/A -$37.4M N/A $13.6M —

Frequently Asked Questions

Allarity Therapeutics, Inc. (ALLR) reported $320K in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Allarity Therapeutics, Inc. (ALLR) reported a net loss of $11.2M in fiscal year 2025.

Allarity Therapeutics, Inc. (ALLR) has a return on equity of -114.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Allarity Therapeutics, Inc. (ALLR) recorded an outflow of $14.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Allarity Therapeutics, Inc. (ALLR) recorded an outflow of $14.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Allarity Therapeutics, Inc. (ALLR) had $18.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Allarity Therapeutics, Inc. (ALLR) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Allarity Therapeutics, Inc. (ALLR) invested $6.6M in research and development during fiscal year 2025.

Yes, Allarity Therapeutics, Inc. (ALLR) spent $3.2M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Allarity Therapeutics, Inc. (ALLR) had 16M shares outstanding as of fiscal year 2025.

Allarity Therapeutics, Inc. (ALLR) had a current ratio of 2.13 as of fiscal year 2025, which is generally considered healthy.

Allarity Therapeutics, Inc. (ALLR) had a liabilities-to-equity ratio of 0.86 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Allarity Therapeutics, Inc. (ALLR) had a return on assets of -61.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Allarity Therapeutics, Inc. (ALLR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $13.8M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Allarity Therapeutics, Inc. (ALLR) trades at 39.5x sales, its market capitalization divided by $350K revenue, trailing 12 months to September 30, 2026. The market capitalization is $13.8M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Allarity Therapeutics, Inc. (ALLR) held $14.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $14.8M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Allarity Therapeutics, Inc. (ALLR) has an Altman Z-Score of -10.63, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Allarity Therapeutics, Inc. (ALLR) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Allarity Therapeutics, Inc. (ALLR) reported a net loss of $11.2M while operations used $14.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Allarity Therapeutics, Inc. (ALLR) reported an operating loss of $12.6M against $185K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top